Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Caron Rigden (NPI 1407903826)

Field	Value
Entity Type	Individual
Organization	Caron Rigden
Address	150 Entrance Way
City	Saint Peters
State	MO
ZIP	63376
Taxonomy	Medical Oncology Physician
NPI Enumerated	January 5, 2007

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This provider reports $1.6M in total Medicare revenue and has no Medicaid billing on file, making the practice effectively single-payer with Medicare as the primary (and only reported) source of public-payer volume. That concentration means analyses of utilization and reimbursement should be Medicare-focused rather than split across payers.

Revenue is highly concentrated in a very small set of biologic infusion codes: J9144, J9271 and J1561 are the top three drivers and together account for 75.9% of the provider's total Medicare revenue. Individually those codes are J9144 (36.3% of Medicare revenue, $581.4K), J9271 (31.7% of Medicare revenue, $507.4K) and J1561 (8.0% of Medicare revenue, $128.1K), so most revenue is coming from a few high-cost injectable therapies.

The code mix and volumes indicate an infusion-focused medical oncology practice: high claim counts and revenue for J9144 (15.3K claims, $581.4K) and J9271 (11.8K claims, $507.4K) alongside chemotherapy administration codes such as 96413 (644 claims, $64.4K) point to routine in-office/clinic administration of oncology biologics and systemic therapies. Supportive care drugs are also present (e.g., J1442 reported as 44.4K claims, $44.4K and J2506 360 claims, $29.5K), consistent with an outpatient infusion operation that supplies growth factors.

On competitive standing, the provider appears a modest-to-typical national participant for its top biologics: J9144 ranks #90 of 615 nationally (85th percentile; described as typical, unremarkable volume), J9271 ranks #967 of 1841 (47th percentile; typical, unremarkable), and J1561 ranks #95 of 180 (47th percentile; typical, unremarkable). These rankings suggest the practice is not an outsized national leader for these agents despite them dominating the provider's Medicare revenue.

Several procedural and blood‑product codes show unusually high relative activity, indicating above-average infusion and transfusion procedures: 96413 ranks #337 of 7514 (95th percentile; notably above typical national volume), 96372 ranks #2054 of 58224 (96th percentile; notably above typical national volume), and 36430 ranks #2 of 94 (99th percentile; extreme outlier, far above typical national volume). These signals point to heavier-than-average use of infusion services and vascular access/transfusion procedures compared with peers.

The provider also reports high relative ranking on certain blood-product items in a small national peer set: P9040 (145 claims, $30K) ranks #2 of 13 (92th percentile; typical, unremarkable volume) while P9073 (33 claims, $23.5K) ranks #4 of 4 (0th percentile; described as typical, unremarkable volume). The presence of irradiated and pathogen‑reduced blood components alongside oncology biologics underscores a service mix that includes complex supportive and transfusion care for oncology patients.

Tenure on file shows the NPI was enumerated 2007-01-05 (~19 years ago), indicating a long-established Medicare billing history that supports trend analysis over multiple reimbursement environments. That longevity can help contextualize utilization patterns and any recent shifts in drug mix or procedure volumes.

Business and payer implications: because $1.6M of revenue is concentrated in a handful of high-cost infused biologics (top three codes = 75.9% of Medicare revenue), the practice is exposed to shifts in Medicare reimbursement or utilization of these specific agents. For payer or network analysts this pattern suggests that contracting, utilization management, and oversight efforts targeted at high-cost oncology infusions will have disproportionate impact on this provider's revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

47 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	15,300	$40	$581.4K
J9271	Injection, pembrolizumab, 1 mg	11,800	$40	$507.4K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	3,370	$40	$128.1K
J0897	Injection, denosumab, 1 mg	4,980	$20	$89.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	640	$100	$64.4K
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	44,400	$1	$44.4K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	150	$210	$30K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	360	$80	$29.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	300	$100	$28.2K
P9073	Platelets, pheresis, pathogen-reduced, each unit	30	$710	$23.5K

Showing 1–10 of 47

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 47 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Caron Rigden — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

47 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	40	9,100	$40	$502K
J9144	3	20	7,200	$40	$308.4K
J1561	6	30	1,650	$40	$87.1K
J0897	47	210	2,400	$20	$82.4K
P9073	2	10	40	$710	$27.1K
J2506	13	40	310	$80	$25.9K
96413	6	160	140	$100	$19.1K
J3490	6	80	40	$150	$14K
99214	1,693	8,960	100	$80	$13.9K
J1442	1	10	11,400	$1	$12.3K

Showing 1–10 of 47

Related Providers

Other providers that share a Tax Identification Number (TIN) with Caron Rigden, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Washington University	MO	Multi-Specialty Clinic/Center	$0	$22M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$14.8M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$10.4M
Washington University	MO	Emergency Care Clinic/Center	$0	$9.1M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$6.9M
Washington University	MO	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$4.4M
Washington University	MO	Multi-Specialty Clinic/Center	$0	$4M
John Visconti	IL	Medical Oncology Physician	$2.8M	$149.1K
Peter Oppelt	MO	Medical Oncology Physician	$2.5M	$15.8K
Ronald Dean	MT	Emergency Medicine Physician	$2.3M	$2.3K

Nearby Providers

Other providers in the same ZIP code as Caron Rigden, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Handicap Facilities Of St Charles County	MO	Case Management Agency	$0	$29.7M
Commun Ity Living For The Handicapped Inc.	MO	Developmentally Disabled Services Day Training Agency	$0	$25.6M
Community Living For The Handicapped Inc.	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$23.7M
Delta Center Personal Attendant Services	MO	In Home Supportive Care Agency	$0	$22.5M
St. Charles County Ambulance District	MO	Land Ambulance	$3.4M	$10.7M
Shanee Woodard	MO	In Home Supportive Care Agency	$0	$8.8M
Resolutions For People, LLC	MO	In Home Supportive Care Agency	$0	$7.9M
Mcclay Adult Day Center LLC	MO	Adult Day Care Clinic/Center	$0	$4.8M
Barnes Jewish St Peters Hospital Inc	MO	General Acute Care Hospital	$0	$4.4M
Ashley Frith	MO	Medical Oncology Physician	$1.4M	$0

Caron Rigden — Billing Profile & Reimbursement Data

Sign up for Caron Rigden — Billing Profile & Reimbursement Data policy alerts

Caron Rigden — Billing Profile & Reimbursement Data

Sign up for Caron Rigden — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References